KOBO Biotech
BSE: 531541
₹ 3.94▼ 0.08 (−1.99%)28 Oct, 01:15 pm IST
- Market cap
- ₹ 10 Cr.
- P/E
- 3.4x
- 52-week range
- 1.99 – 9.99
- ROCE
- −125.6%
- Dividend yield
- 0%
- Sector
- Chemicals & Petrochemicals
- Industry
- Commodity Chemicals
- Listed on
- BSE
About
Kobo Biotech Limited is an India-based company. The Company's business segment is manufacturing active pharmaceutical ingredients (APIs)/bulk drugs. The Company is in the corporate insolvency resolution process.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Commodity Chemicals: 75 companies →KOBO Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)3.4 against a typical 22.7: cheaper than most peers (1st = cheapest).3rd of 72
- Share price, 3 months−53% against a typical −2.2%.64th of 65
- Size₹ 9.8 Cr. market value against a typical ₹ 131.2 Cr. (1st = largest).64th of 69
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 1 | 0 | 9 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | −1 | −0 | −9 | −0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −2 | −1 | −10 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −2 | −1 | −10 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 |
| EPS in Rs | −0.78 | −0.57 | −4.37 | −0.62 | −0.46 | −0.5 | −0.75 | −0.52 | −0.51 | −0.52 | −0.53 | −0.56 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Compounded Profit Growth
- 10 Years
- 6%
- 5 Years
- 12%
- 3 Years
- 18%
- TTM
- −6%
Stock Price CAGR
- 10 Years
- −5%
- 5 Years
- −2%
- 3 Years
- 11%
- TTM
- —
Return on Equity
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Peers
Listed companies in the same business.
| KOBO Biotech | ₹ 3.94 | ₹ 10 Cr. | 3.4x | — | — | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 35.4x | 5.1x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 97x | 15.2x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72x | 19x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.4x | 4.3x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,08,738 Cr. | 124.1x | 20.9x | — | 15% |
Management
- Ajit A. Kamath
- Non-Executive Chairman of the Board, Managing Director
Prices are delayed and for information only. Nothing on this page is investment advice.